# Amycretin

One peptide that does the job of both halves of CagriSema. Novo Nordisk has renamed it zenagamtide.

Also called: Zenagamtide
Source page: https://peplogue.com/peptides/amycretin/
Reviewed: 2026-10-12. Not medical advice.

## How it works

- Where it acts: GLP-1 and amylin receptors, reached by one molecule.
- What it changes: Both fullness signals from a single drug.
- What people notice: Early trials showed large weight loss. Stomach side effects are common.

## What the evidence shows

- **Weight loss**: Supported. Early trials of the weekly injection reported about 22% to 24% loss at 36 weeks. A phase 2 trial in type 2 diabetes reported up to 14.5% at 36 weeks.

## Side effects and risks

- common: Nausea and vomiting, as with other drugs in this class.
- unknown: Longer-term safety is not known.

Who should avoid it: Anyone outside a clinical trial.

## How it has been given in trials

Weekly injection under the skin or a daily tablet, with the dose raised in steps. There is no approved dose.

## Legal status

- United States: undefined
- European Union: undefined
- Spain: undefined. Investigational. No authorised product in Spain (not in CIMA). The only lawful route is a clinical trial; Spanish trial sites not verified.
- Germany: undefined. Not authorised in Germany. Only available in clinical trials; sale outside trials is unlawful under the AMG (§ 21, § 96). German trial sites not checked.
- France: undefined. Investigational drug, not authorised in France. Only lawful route is a trial; ANSM says peptides bought outside the official circuit are illegal.
- Italy: undefined. Investigational. Not authorised in the EU or Italy; only reachable through a clinical trial. Italian trial sites not checked.
- Netherlands: undefined. Experimental. No marketing authorisation in the Netherlands or EU; only in clinical trials. Offering it as a medicine without authorisation is illegal.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**What is amycretin?**

One peptide that acts on both GLP-1 and amylin receptors, doing the job of both halves of CagriSema. Novo Nordisk has renamed it zenagamtide.

**How much weight loss did amycretin give?**

Early trials of the weekly injection reported about 22% to 24% loss at 36 weeks. A phase 2 trial in type 2 diabetes reported up to 14.5% at 36 weeks.

**Is amycretin a pill or an injection?**

Both are being tested. The weekly injection is in several phase 3 trials that began in 2026; Novo planned to start a phase 3 trial of the daily tablet in the third quarter of 2026.

**Is amycretin approved?**

No. The phase 3 program (AMAZE) began in the first half of 2026, and there is no approved dose.

**What are the side effects of amycretin?**

Nausea and vomiting, as with other drugs in this class. Longer-term safety is not known.

## Sources

- Novo Nordisk: full-year 2025 results (name change, phase 2 data): https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm
- Novo Nordisk: half-year report 2026: https://www.sec.gov/Archives/edgar/data/0000353278/000035327826000023/caq22026.htm